{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:48:38Z","timestamp":1762876118740,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.nefro.2019.08.001","type":"journal-article","created":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:37:38Z","timestamp":1573864658000},"page":"171-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efecto regulador de paricalcitol sobre par\u00e1metros inflamatorios, fibr\u00f3ticos y anticalcificantes en el paciente con enfermedad renal cr\u00f3nica. M\u00e1s all\u00e1 de la regulaci\u00f3n de la enfermedad \u00f3seo-mineral"],"prefix":"10.1016","volume":"40","author":[{"given":"Laura","family":"Salanova Villanueva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohana","family":"Gil Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Santos S\u00e1nchez-Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abelardo","family":"Aguilera Peralta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2019.08.001_bib0265","first-page":"3","article-title":"Recomendaciones de la Sociedad Espa\u00f1ola de Nefrolog\u00eda para el manejo de las alteraciones del metabolismo \u00f3seo-mineral en los pacientes con enfermedad renal cr\u00f3nica","volume":"31","author":"Torregrosa","year":"2011","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefro.2019.08.001_bib0270","first-page":"1","article-title":"KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","author":"Isakova","year":"2017","journal-title":"Kidney Int Supplements."},{"key":"10.1016\/j.nefro.2019.08.001_bib0275","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1681\/ASN.2011121191","article-title":"Mechanistic insights into vascular calcification in CKD","volume":"24","author":"Shroff","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0280","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semnephrol.2018.08.001","article-title":"Update on chronic\u00a0kidney disease\u00a0mineral and bone disorder in cardiovascular\u00a0disease","volume":"38","author":"Lunyera","year":"2018","journal-title":"Semin Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0285","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1681\/ASN.2009121311","article-title":"Klotho deficiency causes vascular calcification in chronic kidney disease","volume":"22","author":"Hu","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0290","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2265.2012.04460.x","article-title":"Plasma Fetuin A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver diseas","volume":"78","author":"Roos","year":"2013","journal-title":"Clinical Endocrinology."},{"key":"10.1016\/j.nefro.2019.08.001_bib0295","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1161\/01.RES.00000175571.53833.6c","article-title":"Bone morphogenetic proteins in vascular calcification","volume":"97","author":"Hruska","year":"2005","journal-title":"Circ Res."},{"key":"10.1016\/j.nefro.2019.08.001_bib0300","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/ndt\/gfq313","article-title":"The expanding spectrum of biological actions of vitamin D","volume":"25","author":"Rojas-Rivera","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.nefro.2019.08.001_bib0305","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ki.2012.322","article-title":"receptor agonist increase Klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet","volume":"82","author":"Lau","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.08.001_bib0310","doi-asserted-by":"crossref","first-page":"e008776","DOI":"10.1161\/JAHA.118.008776","article-title":"Vitamin D attenuates endothelial dysfunction in uremic rats and maintains human endothelial stability","volume":"7","author":"Vila Cuenca","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.nefro.2019.08.001_bib0315","first-page":"77","article-title":"Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis","volume":"18","author":"Pi\u00f1era","year":"2013","journal-title":"Nefrolog\u00eda."},{"key":"10.1016\/j.nefro.2019.08.001_bib0320","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1471-2369-13-159","article-title":"Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients","volume":"27","author":"Izquierdo","year":"2012","journal-title":"BMC Nephrology."},{"key":"10.1016\/j.nefro.2019.08.001_bib0325","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.070305","article-title":"Differential\u00a0effects\u00a0of\u00a0vitamin D\u00a0analogs\u00a0on\u00a0vascular calcification","volume":"22","author":"Card\u00fas","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.nefro.2019.08.001_bib0330","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1042\/CS20160807","article-title":"High phosphate induces a pro-inflammatory response by vascular smooth muscle cells and modulation by vitamin D derivatives","volume":"131","author":"Mart\u00ednez-Moreno","year":"2017","journal-title":"Clin Sci."},{"key":"10.1016\/j.nefro.2019.08.001_bib0335","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrcardio.2013.15","article-title":"Management of cardiovascular disease in patients with kidney disease","volume":"10","author":"Kahn","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0340","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1053\/j.ajkd.2012.04.014","article-title":"Associations of plasma 25 Hydroxyvitamin D and 1,25-Dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease","volume":"60","author":"Kendrick","year":"2012","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2019.08.001_bib0345","first-page":"72","article-title":"Inflammation and oxidative stress in ESRD \u2013 the role of myeloperoxidase","volume":"17","author":"Maruyama","year":"2004","journal-title":"J Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0350","first-page":"59","article-title":"Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patient","volume":"22","author":"Capuano","year":"2009","journal-title":"J Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0355","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective Vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"Zeeuw","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2019.08.001_bib0360","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","article-title":"Antiproteinuric effect of oral paricalcitol in chronic kidney disease","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.08.001_bib0365","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.283.5406.1317","article-title":"Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators","volume":"283","author":"Yanagisawa","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.nefro.2019.08.001_bib0370","article-title":"Selective Vitamin D receptor activation as anti-inflammatory target in chronic kidney disease","author":"Donate","year":"2014","journal-title":"Mediators of Inflammation."},{"key":"10.1016\/j.nefro.2019.08.001_bib0375","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J Clin Invest."},{"key":"10.1016\/j.nefro.2019.08.001_bib0380","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1681\/ASN.2006091028","article-title":"Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats","volume":"18","author":"Mizobuchi","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0385","doi-asserted-by":"crossref","first-page":"F801","DOI":"10.1152\/ajprenal.00338.2010","article-title":"Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism","volume":"300","author":"Wang","year":"2011","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0390","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1359\/jbmr.07s217","article-title":"Receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells","volume":"22","author":"Penna","year":"2007","journal-title":"Journal Of Bone And Mineral Research."},{"key":"10.1016\/j.nefro.2019.08.001_bib0395","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4049\/jimmunol.178.1.145","article-title":"1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells","volume":"178","author":"Penna","year":"2007","journal-title":"J Immunol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0400","doi-asserted-by":"crossref","first-page":"e108477","DOI":"10.1371\/journal.pone.0108477","article-title":"Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 Production","volume":"9","author":"Gonz\u00e1lez-Mateo","year":"2014","journal-title":"Plos One."},{"key":"10.1016\/j.nefro.2019.08.001_bib0405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1542-4758.2010.00514.x","article-title":"Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size","volume":"15","author":"Vulpio","year":"2011","journal-title":"Hemodial Int."},{"key":"10.1016\/j.nefro.2019.08.001_bib0410","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11255-014-0842-7","article-title":"Low-dose cholecalciferol supplementation and dual vitamin D\u00a0therapy\u00a0in haemodialysis\u00a0patients","volume":"47","author":"Mittman","year":"2015","journal-title":"Int Urol Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0415","first-page":"59","article-title":"Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patient","volume":"22","author":"Capuano","year":"2009","journal-title":"J Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0420","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1681\/ASN.2010111190","article-title":"Klotho. An elixir of youth for the vasculature?","volume":"22","author":"Shroff","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.08.001_bib0425","first-page":"1150","article-title":"Soluble Klotho protects against uremic cardiomyopathy independently of Fibroblast Growth Factor 23 and phosphate","volume":"26","author":"Xie","year":"2015","journal-title":"J AmSoc Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0430","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/ncomms2240","article-title":"Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart","volume":"3","author":"Xie","year":"2012","journal-title":"Nat Commun."},{"key":"10.1016\/j.nefro.2019.08.001_bib0435","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2337\/db10-1262","article-title":"Klotho depletion contributes to increased inflam-mation in kidney of the db\/db mouse model of diabetes via RelA (serine)536 phosphorylation","volume":"60","author":"Zhao","year":"2011","journal-title":"Diabetes."},{"key":"10.1016\/j.nefro.2019.08.001_bib0440","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1681\/ASN.2010101073","article-title":"The inflammatory cytokines TWEAK and TNF a reduce renal Klotho expression through NF-kB","volume":"22","author":"Moreno","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0445","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/ndt\/gfs160","article-title":"The emerging role of Klotho in clinical nephrology","volume":"27","author":"Hu","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.08.001_bib0450","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.08.001_bib0455","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.03270314","article-title":"Effect of cinacalcet and Vitamin D analogs on Fibroblast Growth Factor-23 during the treatment of secondary hyperparathyroidism","volume":"10","author":"Sprague","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0460","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ki.2013.3","article-title":"Fibroblast Growth Factor 23 is not associated with and does not induce arterial calcification","volume":"83","author":"Scialla","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.08.001_bib0465","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2215\/CJN.09570912","article-title":"Serum FGF 23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology","volume":"8","author":"\u00c4rnl\u00f6v","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0470","first-page":"13","article-title":"Fibroblast Growth Factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort","volume":"24","author":"Vervloet","year":"2012","journal-title":"Bio Med Central Nephrology."},{"key":"10.1016\/j.nefro.2019.08.001_bib0475","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF 23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0480","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/ki.1997.298","article-title":"Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes","volume":"52","author":"Bostom","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.08.001_bib0485","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.intimp.2006.08.015","article-title":"Anti-inflammatory effects of short chain fatty acids in IFN-gammastimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways","volume":"7","author":"Park","year":"2007","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0490","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2006.08.052","article-title":"Association of high alpha2-Heremans-Schmid glycoprotein\/Fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass","volume":"195","author":"Fiore","year":"2007","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.nefro.2019.08.001_bib0495","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/01.ASN.0000109671.99498.08","article-title":"Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model","volume":"15","author":"Lund","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.08.001_bib0500","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.mnh.0000133974.24935.fe","article-title":"Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease","volume":"13","author":"Li Tingting","year":"2004","journal-title":"Current Opinion in Nephrology & Hypertension"},{"key":"10.1016\/j.nefro.2019.08.001_bib0505","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<37::AID-JCP4>3.0.CO;2-M","article-title":"Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro","volume":"184","author":"Dorai","year":"2000","journal-title":"J Cellular Physiol."},{"key":"10.1016\/j.nefro.2019.08.001_bib0510","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11883-015-0509-6","article-title":"Fibroblast growth factor signaling in the vasculature","volume":"17","author":"Yang","year":"2015","journal-title":"Curr Atheroscler Rep."},{"key":"10.1016\/j.nefro.2019.08.001_bib0515","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1089\/scd.2013.0528","article-title":"Mesenchymal stem cells recruited by active TGFb contribute to osteogenic vascular calcification","volume":"23","author":"Wang","year":"2014","journal-title":"Stem Cells and Development."},{"key":"10.1016\/j.nefro.2019.08.001_bib0520","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1681\/ASN.2008121226","article-title":"New insights into epithelial-mesenchymal transition in kidney fibrosis","volume":"21","author":"Liu","year":"2010","journal-title":"J Am Soc Nephrol."}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519301602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519301602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:53:55Z","timestamp":1759323235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699519301602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0211699519301602"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2019.08.001","relation":{},"ISSN":["0211-6995"],"issn-type":[{"type":"print","value":"0211-6995"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efecto regulador de paricalcitol sobre par\u00e1metros inflamatorios, fibr\u00f3ticos y anticalcificantes en el paciente con enfermedad renal cr\u00f3nica. M\u00e1s all\u00e1 de la regulaci\u00f3n de la enfermedad \u00f3seo-mineral","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2019.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}